Literature DB >> 1084890

Studies on human antihemophilic factor. Evidence for a covalently linked subunit structure.

M E Switzer, P A McKee.   

Abstract

When purified antihemophilic factor (Factor VIII) was rechromatographed on 4% agarose in 0.15 M NaCl or 1.0 M NaCl, a single protein peak, containing both procoagulant activity and von Willebrand factor activity, as defined by ristocetin-induced platelet aggregation, was eluted in the void volume. Purified Factor VIII immediately lost about 30% of its procoagulant activity when dissolved in 0.25 M CaCl2, and when rechromatographed on 4% agarose in 0.25 M CaCl2, the protein peak and von Willebrand factor activity remained coincident in the void volume; however, most of the remaining procoagulant activity was eluted after the void volume. The elution position of Factor VIII procoagulant activity from 4% agarose in 0.25 M CaCl2, and hence its apparent molecular weight, varied with the protein concentration applied to the column; at low protein concentrations it was eluted close to the inner volume. Yet on Sephadex G-200 in 0.25 M CaCl2, the protein and procoagulant activity were eluted together in the void volume. These observations suggested that the Factor VIII procoagulant activity was not eluting according to size or shape, but was adsorbing to some extent to the agarose. Isolated activity peak material from the 0.25 M CaCl2 columns contained protein and had a typical ultraviolet spectrum. Even at high concentrations, the protein contained no thrombin, Factors IX, X, or Xa activity, or detectable phospholipid. In addition to Factor VIII procoagulant activity, which could be inactivated by a human antibody to Factor VIII, the activity peak protein also contained von Willebrand factor activity. Like native Factor VIII and the void volume protein, the activity peak contained protein that did not enter a sodium dodecyl sulfate 5% polyacrylamide gel in the absence of reducing reagent. After reduction of disulfide bonds, several subunits ranging from 195,000 to 30,000 daltons were observed. These results indicate that the protein in the shifted Factor VIII procoagulant activity peak is large and that its anomalous elution pattern from 4% agarose in 0.25 M CaCl2 results from interaction with the agarose. The Factor VIII-like properties of the activity peak protein and its electrophoretic pattern on sodium dodecyl sulfate gels suggest that it is a species of Factor VIII modified by proteolytic cleavage. These results allow an interpretation that is different from the recently proposed "carrier protein-small active subunit" hypotheses for the structure-function relationships of the Factor VIII molecule.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1084890      PMCID: PMC436736          DOI: 10.1172/JCI108369

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  The role of polyamines in the neutralization of bacteriophage deoxyribonucleic acid.

Authors:  B N AMES; D T DUBIN
Journal:  J Biol Chem       Date:  1960-03       Impact factor: 5.157

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Letter: Experimental model for von Willebrand's disease.

Authors:  D Meyer; C S Jenkins; M Dreyfus; M J Larrieu
Journal:  Nature       Date:  1973-06-01       Impact factor: 49.962

4.  Nature of von Willebrand factor: a new assay and a specific inhibitor.

Authors:  K E Sarji; R D Stratton; R H Wagner; K M Brinkhous
Journal:  Proc Natl Acad Sci U S A       Date:  1974-08       Impact factor: 11.205

5.  Von Willebrand factor: dissociation from antihemophilic factor procoagulant activity.

Authors:  H J Weiss; I W Hoyer
Journal:  Science       Date:  1973-12-14       Impact factor: 47.728

6.  Studies on the nature of antihemophilic factor (factor VIII). Further evidence relating the AHF-like antigens in normal and hemophilic plasmas.

Authors:  B Bennett; W B Forman; O D Ratnoff
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

7.  The subunit structure of normal and hemophilic factor VIII.

Authors:  G A Shapiro; J C Andersen; S V Pizzo; P A McKee
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

8.  Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII.

Authors:  H J Weiss; J Rogers; H Brand
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

9.  The defect in hemophilic and von Willebrand's disease plasmas studied by a recombination technique.

Authors:  H A Cooper; R H Wagner
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

10.  Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.

Authors:  H J Weiss; L W Hoyer; F R Rickles; A Varma; J Rogers
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

View more
  25 in total

1.  Von Willebrand's disease.

Authors: 
Journal:  Br Med J       Date:  1976-09-25

2.  Demonstration and characterization of specific binding sites for factor VIII/von Willebrand factor on human platelets.

Authors:  K J Kao; S V Pizzo; P A McKee
Journal:  J Clin Invest       Date:  1979-04       Impact factor: 14.808

3.  The properties of immune complexes formed by human antibodies to factor VIII.

Authors:  J Lazarchick; L W Hoyer
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

4.  Effect of phospholipases on factor-VIII activity.

Authors:  R Ananthakrishnan; S D'Souza
Journal:  Hum Genet       Date:  1978-01-19       Impact factor: 4.132

Review 5.  Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Authors:  Steven W Pipe; Robert R Montgomery; Kathleen P Pratt; Peter J Lenting; David Lillicrap
Journal:  Blood       Date:  2016-09-01       Impact factor: 22.113

6.  Macromolecular factor VIII complex: functional and structural heterogeneity observed in von Willebrand swine with transfusion.

Authors:  T R Griggs; J S Potter; S B McClanahan; W P Webster; K M Brinkhous
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

7.  Platelet receptors for human Factor VIII/von Willebrand protein: functional correlation of receptor occupancy and ristocetin-induced platelet aggregation.

Authors:  K J Kao; S V Pizzo; P A McKee
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

8.  Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation.

Authors:  A B Federici; J H Elder; L De Marco; Z M Ruggeri; T S Zimmerman
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

9.  von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIB von Willebrand disease.

Authors:  J L Miller; J M Kupinski; A Castella; Z M Ruggeri
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

10.  Some effects of calcium on the activation of human factor VIII/Von Willebrand factor protein by thrombin.

Authors:  M E Switzer; P A McKee
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.